Study Details

A Study to Assess the Efficacy and Safety of ASKP1240 in de novo Kidney Transplant Recipients

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01780844

Astellas Study ID

The unique identification code given by the study sponsor.

7163-CL-0108

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Condition

Kidney Transplants

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Mar 2013 - Jan 2017

Masking

None (Open Label)

Enrollment number

149

A Phase 2a, Randomized, Open-label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de novo Kidney Transplant Recipients

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Efficacy and Safety of ASKP1240 in de novo Kidney Transplant Recipients? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US10015

Lexington, United States, 40536

Site US10026

Greenville, United States, 27834

Site US10019

Bronx, United States, 10467

Site US10003

San Francisco, United States, 94143

Site US10001

Dallas, United States, 75246

Site US10017

Ann Arbor, United States, 48109

Site US10044

Houston, United States, 77030

Site US10016

Durham, United States, 27710

Site US10035

Nashville, United States, 37232-4750

Site US10014

Baltimore, United States, 21201

Site US10018

Chicago, United States, 60612

Site US10007

Atlanta, United States, 30322

Site US10010

Chicago, United States, 60612

Site US10031

Buffalo, United States, 14215

Site US10027

Harrisburg, United States, 17011

Site US10009

Cincinnati, United States, 45267

Site US10033

Salt Lake City, United States, 84132

Site US10020

Charlottesville, United States, 22908

Site US10037

Chicago, United States, 60637

Site US10013

Aurora, United States, 80045

Site US10040

Cleveland, United States, 44106

Site US10042

Charlotte, United States, 28203

Site US10032

Cleveland, United States, 44195

Site US10023

New York, United States, 10065

Site US10008

Los Angeles, United States, 90057

Site US10012

Charleston, United States, 29425

Site US10025

St. Louis, United States, 63110

Site US10045

New Orleans, United States, 70112

Site US10004

San Francisco, United States, 94115

Site US10021

Palo Alto, United States, 94304

Site US10030

San Diego, United States, 92123

Site US10005

Madison, United States, 53792

Site US10036

Chapel Hill, United States, 27599

Site US10024

Phoenix, United States, 85054

Site US10034

New York, United States, 10029

Site US10029

Houston, United States, 77030

Site US10041

Augusta, United States, 30912

Site US10002

Fort Worth, United States, 76104

Site US10006

Birmingham, United States, 35233

Site US10038

Pittsburgh, United States, 15213

Site US10022

Livingston, United States, 07039

Site US10028

Memphis, United States, 38104